Carisma Therapeutics, Inc.2024财年第三财季实现净利润-12.70百万美元，同比增加40.65%

市场透视11-16

11月16日，Carisma Therapeutics, Inc.（CARM.US）公布财报，公告显示公司2024财年第三财季净利润为-12.70百万美元，同比增加40.65%；其中营业收入为3.39百万美元，同比减少11.49%，每股基本收益为-0.31美元。从资产负债表来看，Carisma Therapeutics, Inc.（CARM.US）总负债53.18百万美元，其中短期债务2.46...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483306149?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483306149","market":"us","top_or_hot":-1,"title":"Carisma Therapeutics, Inc.2024财年第三财季实现净利润-12.70百万美元，同比增加40.65%","media":"市场透视","content":"<div>\n<p>11月16日，Carisma Therapeutics, Inc.（CARM.US）公布财报，公告显示公司2024财年第三财季净利润为-12.70百万美元，同比增加40.65%；其中营业收入为3.39百万美元，同比减少11.49%，每股基本收益为-0.31美元。从资产负债表来看，Carisma Therapeutics, Inc.（CARM.US）总负债53.18百万美元，其中短期债务2.46...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000321a23b89e2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Carisma Therapeutics, Inc.2024财年第三财季实现净利润-12.70百万美元，同比增加40.65%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCarisma Therapeutics, Inc.2024财年第三财季实现净利润-12.70百万美元，同比增加40.65%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000321a23b89e2&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Carisma Therapeutics, Inc.（CARM.US）公布财报，公告显示公司2024财年第三财季净利润为-12.70百万美元，同比增加40.65%；其中营业收入为3.39百万美元，同比减少11.49%，每股基本收益为-0.31美元。从资产负债表来看，Carisma Therapeutics, Inc.（CARM.US）总负债53.18百万美元，其中短期债务2.46...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000321a23b89e2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000321a23b89e2&s=b","article_id":"2483306149","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000321a23b89e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483306149","pubTimestamp":1731686435,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Carisma Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-12.70百万美元，同比增加40.65%；其中营业收入为3.39百万美元，同比减少11.49%，每股基本收益为-0.31美元。从资产负债表来看，Carisma Therapeutics, Inc.总负债53.18百万美元，其中短期债务2.46百万美元，资产负债比为0.80，流动比率为3.24。机构评级：截至2024年11月16日，当前有4家机构对Carisma Therapeutics, Inc.目标价做出预测，其中目标均价为11.00美元，其中最低目标价为4.00美元，最高目标价为24.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","CARM":"Carisma Therapeutics"},"translate_title":"Carisma Therapeutics, Inc. achieved net profits of-US $12.70 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 40.65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARM":1,"LENZ":1},"content_text":"11月16日，Carisma Therapeutics, Inc.（CARM.US）公布财报，公告显示公司2024财年第三财季净利润为-12.70百万美元，同比增加40.65%；其中营业收入为3.39百万美元，同比减少11.49%，每股基本收益为-0.31美元。从资产负债表来看，Carisma Therapeutics, Inc.（CARM.US）总负债53.18百万美元，其中短期债务2.46百万美元，资产负债比为0.80，流动比率为3.24。机构评级：截至2024年11月16日，当前有4家机构对Carisma Therapeutics, Inc.目标价做出预测，其中目标均价为11.00美元，其中最低目标价为4.00美元，最高目标价为24.00美元。公司简介：CARISMA Therapeutics Inc 是一家临床阶段的细胞治疗公司，致力于利用 Carisma 专有的嵌合抗原受体巨噬细胞和单核细胞细胞工程平台开发治疗癌症和其他严重疾病的变革性免疫疗法。公司曾创建了一个全面的细胞治疗平台，使工程巨噬细胞和单核细胞的治疗用途成为可能，巨噬细胞和单核细胞属于白细胞的一个亚群，称为髓系细胞。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483306149"}